EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Narrative Review of the Role of Adjuvants in Adult RSV Vaccines

Elizabeth Williams, Giovanni Checcucci Lisi, Kate Luisi, Kumar Ilangovan, Negar Aliabadi, Cassandra Hall-Murray, Pier Luigi Lopalco, Edward Walsh, Kyla Hayford, Elizabeth Begier

Vaccines · 27.10.2026 · 14 (11) · 932

DOI: 10.3390/vaccines14110932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 27.10.2026. Verfasst von Elizabeth Williams und 9 weiteren Autor:innen. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc..

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of respiratory syncytial virus (RSV) vaccines has advanced substantially in recent years, with three prefusion F (preF) protein-based and mRNA platforms achieving regulatory approval for use in older adults. Among licensed protein subunit vaccines, key design differences include the use of adjuvants and antigen valency, raising important questions regarding the necessity and impact of adjuvantation for RSV prevention. This narrative review examines the role of adjuvants in RSV vaccine development, with a focus on immunogenicity, vaccine effectiveness, safety, and implications for older adults and immunocompromised (IC) populations. Adjuvants can sometimes enhance immune responses but may increase reactogenicity. Clinical trials and observational studies demonstrate that both adjuvanted (RSVPreF3/AS01E) and non-adjuvanted (bivalent RSVpreF) vaccines provide substantial and comparable protection against RSV-related lower respiratory tract disease and hospitalization with comparable safety. The totality of evidence to date does not suggest an effectiveness advantage for adjuvanted vaccines among IC populations. Overall, these findings suggest that effective protection against RSV disease in adults can be achieved with or without adjuvantation.

Förderung

  • Pfizer Inc.

Zitieren

APA

Williams, E., Lisi, G. C., Luisi, K., Ilangovan, K., Aliabadi, N., Hall-Murray, C., Lopalco, P. L., Walsh, E., Hayford, K., & Begier, E. (2026). A Narrative Review of the Role of Adjuvants in Adult RSV Vaccines. Vaccines, 14(11), 932. https://doi.org/10.3390/vaccines14110932

Vancouver

Williams E, Lisi GC, Luisi K, Ilangovan K, Aliabadi N, Hall-Murray C, et al. A Narrative Review of the Role of Adjuvants in Adult RSV Vaccines. Vaccines. 2026;14(11):932. doi:10.3390/vaccines14110932

BibTeX
@article{Williams2026,
  author = {Williams, Elizabeth and Lisi, Giovanni Checcucci and Luisi, Kate and Ilangovan, Kumar and Aliabadi, Negar and Hall-Murray, Cassandra and Lopalco, Pier Luigi and Walsh, Edward and Hayford, Kyla and Begier, Elizabeth},
  title = {A Narrative Review of the Role of Adjuvants in Adult RSV Vaccines},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {11},
  pages = {932},
  doi = {10.3390/vaccines14110932}
}
Kostenlos starten →